Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.952 EUR
−93.48 M EUR
698.35 K EUR
51.49 M
About CELLECTIS
Sector
CEO
André Choulika
Headquarters
Paris
Website
Founded
1999
ISIN
FR0010425595
FIGI
BBG000BFWPZ4
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange CELLECTIS NOM. EO-,05 stocks are traded under the ticker ZVA.
We've gathered analysts' opinions on CELLECTIS NOM. EO-,05 future price: according to them, ZVA price has a max estimate of 9.17 EUR and a min estimate of 2.75 EUR. Watch ZVA chart and read a more detailed CELLECTIS NOM. EO-,05 stock forecast: see what analysts think of CELLECTIS NOM. EO-,05 and suggest that you do with its stocks.
Yes, you can track CELLECTIS NOM. EO-,05 financials in yearly and quarterly reports right on TradingView.
CELLECTIS NOM. EO-,05 is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
ZVA earnings for the last quarter are −0.21 EUR per share, whereas the estimation was −0.22 EUR resulting in a 3.09% surprise. The estimated earnings for the next quarter are −0.17 EUR per share. See more details about CELLECTIS NOM. EO-,05 earnings.
CELLECTIS NOM. EO-,05 revenue for the last quarter amounts to 16.56 M EUR, despite the estimated figure of 4.94 M EUR. In the next quarter, revenue is expected to reach 9.04 M EUR.
ZVA net income for the last quarter is −20.99 M EUR, while the quarter before that showed −23.47 M EUR of net income which accounts for 10.59% change. Track more CELLECTIS NOM. EO-,05 financial stats to get the full picture.
No, ZVA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 14, 2024, the company has 221.00 employees. See our rating of the largest employees — is CELLECTIS NOM. EO-,05 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CELLECTIS NOM. EO-,05 EBITDA is −65.90 M EUR, and current EBITDA margin is −11.67 K%. See more stats in CELLECTIS NOM. EO-,05 financial statements.
Like other stocks, ZVA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CELLECTIS NOM. EO-,05 stock right from TradingView charts — choose your broker and connect to your account.